Report Overview
The increasing prevalence of ADHD among children and adults, along with rising awareness about mental health treatment, is driving this growth.
The Dextroamphetamine Sulfate API market refers to the industry involved in the production and distribution of the active pharmaceutical ingredient (API) used in medications for treating disorders such as Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and certain forms of depression.
Dextroamphetamine sulfate is a central nervous system stimulant, widely recognized for its role in increasing dopamine and norepinephrine levels in the brain, enhancing concentration, and reducing impulsivity.
Market Analysis
The global Dextroamphetamine
Sulfate
API Market was valued at US$ 60.1 million in 2024 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9%, reaching US$ 81.2 million by 2032.
Regional Analysis
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Competitor Analysis
Johnson Matthey
Cambrex
Ashland
Curia Global
Mallinckrodt Pharmaceuticals
Market Segmentation
